A comprehensive review of regulatory test methods for endocrine adverse health effects

References

• Ahmed OM, El-Gareib AW, El-Bakry AM, Abd El-Tawab SM, Ahmed RG. 2008. Thyroid hormones states and brain development interactions. Int J Dev Neurosci. 26:147–209.
   PubMed Web of Science ®Google Scholar
• Ankley GA, Bennett RE, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, Mount DR, Nichols JW, Russom CL, Schmieder PK, et al. 2010. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem. 29:730–741.
   PubMed Web of Science ®Google Scholar
• Ankley GT, Gray LE. 2013. Cross-species conservation of endocrine pathways: a critical analysis of tier 1 fish and rat screening assays with 12 model chemicals. Environ Toxicol Chem. 32:1084–1087.
   PubMed Web of Science ®Google Scholar
• Bay K, Asklund C, Skakkebaek NE, Andersson AM. 2006. Testicular dysgenesis syndrome: possible role of endocrine disrupters. Best Pract Res Clin Endocrinol Metab. 20:77–90.
   PubMed Web of Science ®Google Scholar
• Becker RA, Ankley GT, Edwards SW, Kennedy SW, Linkov I, Meek B, Sachana M, Segner H, Van Der Burg B, Villeneuve DL, Watanabe H. 2015. Increasing scientific confidence in adverse outcome pathways: application of tailored Bradford-Hill considerations for evaluating weight of evidence. Regul Toxicol Pharmacol. 72:514–537.
   PubMed Web of Science ®Google Scholar
• Bergman A, Heindel JJ, Kasten T, Kidd KA, Jobling S, Neira M, Zoeller RT, Becher G, Bjerregaard P, Bornman R, et al. 2013. The impact of endocrine disruption: a consensus statement on the state of the science. Environ Health Perspect. 121:104–106.
   PubMed Web of Science ®Google Scholar
• Berlaymont Declaration on Endocrine Disrupters. 2013. [Internet]. Available from: http://www.brunel.ac.uk/__data/assets/pdf_file/0005/300200/The_Berlaymont_Declaration_on_Endocrine_Disrupters.pdf
   Google Scholar
• Bikle DD. 2010. Vitamin D: newly discovered actions require reconsideration of physiologic requirements. Trends Endocrinol Metab. 21:375–384.
   PubMed Web of Science ®Google Scholar
• Blair E, Watson L. 2006. Epidemiology of cerebral palsy. Semin Fetal Neonatal Med. 11:117–125.
   PubMed Web of Science ®Google Scholar
• Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. 2006. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 91:4295–4301.
   PubMed Web of Science ®Google Scholar
• Browne P, Judson RS, Casey WM, Kleinstreuer NC, Thomas RS. 2015. Screening chemicals for estrogen receptor bioactivity using a computational model. Environ Sci Technol. 49:8804–8814.
   PubMed Web of Science ®Google Scholar
• Bruckner-Davis F. 1998. Effects of environmental synthetic chemicals on thyroid function. Thyroid. 8:827–856.
   PubMed Web of Science ®Google Scholar
• Buck Louis GM, Lynch CD, Cooney MA. 2006. Environmental influences on female fecundity and fertility. Semin Reprod Med. 24:147–155.
   PubMed Web of Science ®Google Scholar
• Charbonneau JP, Koger SM. 2008. Plastics, pesticides and PBDEs: endocrine disruption and developmental disabilities. J Dev Phys Disabil. 20:115–128.
   Web of Science ®Google Scholar
• Chester-Jones I, Phillips JG. 1986. The adrenal and internal glands. In: Pang PKT, Schreibman MP, editors. Vertebrate endocrinology. Fundamentals and biomedical implications, vol. I. San Diego, CA: Academic Press; p. 319–349.
   Google Scholar
• Congressional Record Senate. 2016. Supporting the newly enacted TSCA reform bill. S3511. [Internet]. [cited 2016 June 7]. Available from: https://www.congress.gov/crec/2016/06/07/CREC-2016-06-07-pt1-PgS3511.pdf
   Google Scholar
• Connors SL, Levitt P, Matthews SG, Slotkin TA, Johnston MV, Kinney HC, Johnson WG, Dailey RM, Zimmerman AW. 2008. Fetal mechanisms in neurodevelopmental disorders. Pediatr Neurol. 38:163–176.
   PubMed Web of Science ®Google Scholar
• Corton JC, Cunningham ML, Hummmmaner BT, Lau C, Meek B, Peters JM, Popp JA, Rhomberg L, Seed J, Klaunig JE. 2014. Mode of action framework analysis for receptor-mediated toxicity: the peroxisome proliferator-activated receptor alpha (PPARα) as a case study. Crit Rev Toxicol. 44:1–49.
   PubMed Web of Science ®Google Scholar
• Cottrell EC, Ozanne SE. 2007. Developmental programming of energy balance and the metabolic syndrome. Proc Nutr Soc. 66:198–206.
   PubMed Web of Science ®Google Scholar
• Crisp TM, Clegg ED, Cooper RL, Wood WP, Anderson DG, Baitke KP, Hoffman JL, Morrow MS, Rodier DJ, Schaeffer JE, et al. 1998. Environmental endocrine disruption: an effects assessment and analysis. Environ Health Perspect. 106:11–56.
   PubMed Web of Science ®Google Scholar
• Crofton KM. 2008. Thyroid disrupting chemicals: mechanisms and mixtures. Int J Androl. 2:209–223.
   Google Scholar
• Damstra T, Barlow S, Bergman A, Kavlkock R, Van der Kraak G. 2002. Global assessment of the state-of-the-science of endocrine disruptors. Geneva, Switzerland: World Health Organization.
   Google Scholar
• Danks JA, D’Souza DG, Gunn HJ, Milley KM, Richardson RJ. 2011. Evolution of the parathyroid hormone family and skeletal formation pathways. Gen Comp Endocrinol. 170:79–91.
   PubMed Web of Science ®Google Scholar
• Darras VM. 2008. Endocrine disrupting polyhalogenated organic pollutants interfere with thyroid hormone signalling in the developing brain. Cerebellum. 7:26–37.
   PubMed Web of Science ®Google Scholar
• Davis DL, Bradlow HL, Wolff M, Woodruff T, Hoel DG, Nton-Culver H. 1993. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ Health Perspect. 101:372–377.
   PubMed Web of Science ®Google Scholar
• Dellarco V, Fenner-Crisp PA. 2012. Mode of action: moving toward a more relevant and efficient assessment paradigm. J Nutr. 142: 2192S–2198S.
   PubMed Web of Science ®Google Scholar
• Demissie M, Lazic M, Foecking EM, Aird F, Dunaif A, Levine JE. 2008. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol Endocrinol Metab. 295:E262–E268.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC. 2009. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 30:293–342.
   PubMed Web of Science ®Google Scholar
• EDSTAC [Endocrine Disruptor Screening and Testing Advisory Committee]. 1998. Final Report. Available from: http://www.epa.gov/endocrine-disruption/endocrine-disruptor-screening-and-testing-advisory-committee-edstac-final
   Google Scholar
• EEA [European Environment Agency]. 2012. The impacts of endocrine disrupters on wildlife, people and their environments – The Weybridge +15 (1996–2011) Report. EEA Technical Report 2/2012. 112pp.
   Google Scholar
• EFSA [European Food Safety Authority]. 2013. Scientific opinion on the hazard assessment of endocrine disruptors: scientific criteria for identification of endocrine disruptors and appropriateness of existing test methods for assessing effects mediated by these substances on human health and the environment. Parma, Italy. EFSA J. 11:3132.
   Google Scholar
• EU [European Commission]. 2016. Draft Commission Regulation (EU) setting out scientific criteria for the determination of endocrine disrupting properties and amending Annex II to Regulation (EC) 1107/2009. C(2016) 3751 Project. Available from: http://europa.eu/rapid/press-release_IP-16-2152_en.htm
   Google Scholar
• Federal Register. 1998a. Endocrine Disruptor Screening Program. 63:42852 (August 11, 1998).
   Google Scholar
• Federal Register. 1998b. Endocrine Disruptor Screening Program: Statement of Policy; Notice 63:71542 (December 28, 1998).
   Google Scholar
• Feldt-Rasmussen U. 2001. Iodine and cancer. Thyroid. 11:483–486.
   PubMed Web of Science ®Google Scholar
• Geschwind SA, Eiseman E, Spektor D, Hudson A. 1999. The impact of endocrine disruption chemicals in wildlife: a review of the literature 1985-1998. Rand [contract MR-1050.0-OSTP] office of science and technology policy. Washington, DC: Science and Technology Policy Institute. p. 69.
   Google Scholar
• Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller T. 2015. EDC-2: The Endocrine Society’s second scientific statement on endocrine disrupting chemicals. Endocr Rev. 36:E1–E150. DOI: 10.1210/er.2015.1010.
   Web of Science ®Google Scholar
• Greenberg N, Wingfield JC. 1987. Stress and reproduction: reciprocal relationships. In: Norris DO, Jones RE, editors. Reproduction in fishes, amphibians, and reptiles, plenum. New York: Springer; p. 461–503.
   Google Scholar
• Grun F, Blumberg B. 2006. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling. Endocrinology. 147:S50–S55.
   PubMed Web of Science ®Google Scholar
• Harkonen PL, Makela SI. 2004. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol. 92:297–305.
   PubMed Web of Science ®Google Scholar
• Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW. 2007. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab. 92:2610–2615.
   PubMed Web of Science ®Google Scholar
• Howdeshell KL. 2002. A model of the development of the brain as a construct of the thyroid system. Environ Health Perspect. 110:337–348.
   PubMed Web of Science ®Google Scholar
• Huang LW, Pu YB, Alamm S, Birch L, Prins GS. 2004. Estrogenic regulation of signaling pathways and homeobox genes during rat prostate development. J Androl. 25:330–337.
   PubMedGoogle Scholar
• Hunt PA, Sheela S, Fowler PA, Leonardo T. 2016. Female reproductive disorders, diseases, and costs of exposure to endocrine disrupting chemicals in the European Union. J Clin Endocrinol Metab. 101:1562–1570.
   Web of Science ®Google Scholar
• IARC/GLOBOCAN. 2010. IARC Breast cancer factsheet. http://globocan iarcfr/factsheets/cancers/breast asp.
   Google Scholar
• Jonklaas J, Nsouli-Maktabi H, Soldin SJ. 2008. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid. 18:943–952.
   PubMed Web of Science ®Google Scholar
• Judson RS, Magpantay FM, Chicarmane V, Haskell C, Tania N, Taylor J, Xia M, Huang R, Rotroff DM, Filer DL, et al. 2015. Integrated model of chemical perturbations of a biological pathway using 18 in vitro high-throughput screening assays for the estrogen receptor. Toxicol Sci. 148:137–154.
   PubMed Web of Science ®Google Scholar
• Jugan ML, Levi Y, Blondeau JP. 2010. Endocrine disruptors and thyroid hormone physiology. Biochem Pharmacol. 79:939–947.
   PubMed Web of Science ®Google Scholar
• Kampf-Lassin A, Prendergast BJ. 2013. Acute downregulation of type II and type III iodothyronine deiodinases by photoperiod in peripubertal male and female Siberian hamsters. Gen Comp Endocrinol. 193:72–78.
   PubMed Web of Science ®Google Scholar
• Kaplowitz PB, Kemp S. 2015. Precocious puberty. Drugs, diseases and procedures. Available from: http://emedicine.medscape.com/article/924002-overview.
   Google Scholar
• Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, Deluca JG, Lai DY, Mckee RH, Peters JM, et al. 2003. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol. 33:655–780.
   PubMed Web of Science ®Google Scholar
• Koibuchi N. 2008. The role of thyroid hormone on cerebellar development. Cerebellum. 7:530–533.
   PubMed Web of Science ®Google Scholar
• Kortenkamp A, Evans R, Martin O, Mckinlay R, Orton F, Rosivatz E. 2012. State of the art assessment of endocrine disrupters: final report. Annex I State of the Science. European Commission, Directorate General Environment.
   Google Scholar
• Krattenmacher R, Knauthe R, Parczyk K, Walker A, Hilgenfeldt U, Fritzemeier KH. 1994. Estrogen action on hepatic synthesis of angiotensinogen and IGF-I: direct and indirect estrogen effects. J Steroid Biochem Mol Biol. 48:207–214.
   PubMed Web of Science ®Google Scholar
• Lazic M, Aird F, Levine Dunaif A. 2010. Prenatal androgen treatment alters body composition and glucose homeostasis in male rats. J Endocrinol. 208:293–300.
   PubMed Web of Science ®Google Scholar
• Leblanc GA, Norris DO, Kloas W, Kullman SW, Baldwin WS, Greally JM. 2012. Detailed review paper on the state of the science on novel in vitro and in vivo screening and testing methods and endpoints for evaluating endocrine disruptors. OECD Series on Testing & Assessment No. 178. Paris: OECD; p. 213.
   Google Scholar
• Lefebvre P, Benomar Y, Staels B. 2010. Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab. 21:676–683.
   PubMed Web of Science ®Google Scholar
• Licata AA, Lerma EV. (Eds). 2012. Diseases of the parathyroid glands. New York: Springer.
   Google Scholar
• Manole D, Schidknecht B, Gosnell B, Adams E, Derwahl M. 2001. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab. 86:1072–1077.
   PubMed Web of Science ®Google Scholar
• Mansouri K, Abdelaziz A, Rybacka A, Roncaglioni A. 2016. CERAPP: collaborative estrogen receptor activity prediction project. J Environ Health Perspect. 124:1023–1033. DOI: 10.1289/ehp.1510267
   PubMed Web of Science ®Google Scholar
• Martini FH, Ober WC, Garrison CW, Welch K, Hutchings RT. 1995. Fundamentals of anatomy and physiology. Englewood Cliffs (NJ): Prentice Hall; p. 7632.
   Google Scholar
• Mazzaferri EL, Jhiang SM. 1994. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Epidemiol. 120:423–435.
   Google Scholar
• McLachlan JA, Simpson E, Martin M. 2006. Endocrine disrupters and female reproductive health. Best Pract Res Clin Endocrinol Metab. 20:63–75.
   PubMed Web of Science ®Google Scholar
• Mollard S, Mousseau Y, Baaj Y, Richard L, Cook-Moreau J, Montell J, Funalot B, Sturtz FG. 2011. How can grafted breast cancer models be optimized?. Cancer Biol Ther. 12:855–886.
   PubMed Web of Science ®Google Scholar
• Murk AJ, Rjntnes E, Blaauboer BJ, Clewell R, Crofton KM, Dingemans MML, Furlow JD, Kavlock R, Kohrle J, Opitz R, et al. 2013. Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. Toxicol In Vitro. 27:1320–1346.
   PubMed Web of Science ®Google Scholar
• Nagataki S, Nystrom E. 2002. Epidemiology and primary prevention of thyroid cancer. Thyroid. 12:889–896.
   PubMed Web of Science ®Google Scholar
• National Academy of Medicine. 2016. Exploring the intersection of obesity and type 2 diabetes. October 17, 2016. Available from: https://nam.edu/event/2016-nam-annual-meeting/
   Google Scholar
• National Academy of Sciences (NAS). 2016. Ovarian cancers. Evolving paradigms in research and care. Committee on the State of the Science in Ovarian Cancer Research; Board on Health Care Services. Institute of Medicine. National Academies of Sciences Engineering and Medicine.
   Google Scholar
• Nelles JL, Hu W-Y, Prins GS. 2011. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab. 6:437–451. Available from: http://doi.org/10.1586/eem.11.20
   PubMedGoogle Scholar
• Nelson RJ. 1995. An introduction to behavioral endocrinology. Sunderland, MA: Sinauer Associates, Inc.; p. 611.
   Google Scholar
• Newbold RR, Padilla-Banks E, Jefferson WN, Heindel JJ. 2008. Effects of endocrine disruptors on obesity. Int J Androl. 31:201–207.
   PubMed Web of Science ®Google Scholar
• Norris DO, Carr JA. 2013. Vertebrate endocrinology. 5th ed. Amsterdam: Elsevier. Available from: http://booksite.elsevier.com/9780123948151.
   Google Scholar
• NRC [National Research Council]. 1999. Hormonally active agents in the environment. Washington, DC: National Academy Press.
   Google Scholar
• OECD. 2004. Available from: http://www.oecd-ilibrary.org/docserver/download/9750471e.pdf?expires=1456423947&id=id&accname=guest&checksum=2BE1D87F596D57741CFBAF7B25ABB047
   Google Scholar
• OECD. 2012. Guidance document on standardized test guidelines for evaluating chemicals for endocrine disruption. OECD Series on Testing and Assessment No. 150. p. 524.
   Google Scholar
• OECD. 2016. Users’ handbook supplement to the guidance document for developing and assessing adverse outcome pathways, OECD series on the adverse outcome pathway, No. 1. Paris: OECD publishing. [cited 2016 Aug]. Available from: http://ldx.doi.org/10.1787/5jlvm9dlg32-en
   Google Scholar
• Osborne G, Rudel R, Schwarzman M. 2014. Evaluating chemical effects on mammary gland development: a critical need in disease prevention. Reprod Toxicol. 54:148–155.
   Google Scholar
• Ottinger MA, vom Saal FS. 2002. Impact of environmental endocrine disruptors on sexual differentiation in birds and mammals. In: Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE., eds. Hormones, brain and behavior. Vol 4. New York: Elsevier Science and Technology Books; p. 325–383.
   Google Scholar
• Parker WH. 2007. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 87:725–736.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kita M, Efstathiadou Z, Poulakos P, Slavakis A, Sofianou D, Flaris N, Leontsini M, Kourtis A, Avramidis A. 2008. Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol. 134:953–960.
   PubMed Web of Science ®Google Scholar
• Prins GS, Birch Tang WY, Ho SM. 2007. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol. 23:374–382.
   PubMed Web of Science ®Google Scholar
• Rasier G, Toppari J, Parent AS, Bourguignon JP. 2006. Female sexual maturation and reproduction after prepubertal exposure to estrogens and endocrine disrupting chemicals: a review of rodent and human data. Mol Cell Endocrinol. 254:187–201.
   PubMed Web of Science ®Google Scholar
• Reif DM, Martin MT, Tan SW, Houck KA, Judson RS, Richard AM, Knudsen TB, Dix DJ, Kavlock RJ. 2010. Endocrine profiling and prioritization of environmental chemicals using toxcast Data. Environ Health Perspect. 118:1714–1720.
   PubMed Web of Science ®Google Scholar
• Renaville R, Hammadi M, Portetelle D. 2002. Role of the somatotropic axis in the mammalian metabolism. Domest Anim Endocrinol. 23:351–360.
   PubMed Web of Science ®Google Scholar
• Ropero AB, Onso-Magdalena P, Quesada I, Nadal A. 2008. The role of estrogen receptors in the control of energy and glucose homeostasis. Steroids. 73:874–879.
   PubMed Web of Science ®Google Scholar
• Rotroff DM, Martin MT, Dix DJ, Filer DL, Houck KA, Knudsen TB, Sipes NS, Reif DM, Xia M, Huang R, Judson RS. 2014. Predictive endocrine testing in the 21st century using in vitro assays of estrogen receptor signaling responses. Environ Sci Technol. 48:8706–8716.
   PubMed Web of Science ®Google Scholar
• Russo J, Russo IH. 1996. Experimentally induced mammary tumors in rats. Breast Cancer Res Treat. 39:7–20.
   PubMed Web of Science ®Google Scholar
• Sargis RM, Johnson DN, Choudry RA, Brady MJ. 2010. Environmental endocrine disruptors promote adipogenesis in the 3T3-L1 cell line through glucocorticoid receptor activation. Obesity (Silver Spring). 18:1283–1288.
   PubMed Web of Science ®Google Scholar
• SEC (2007)1635. 2007. Commission Staff Working Document on the implementation of the "Community Strategy for Endocrine Disrupters" - a range of substances suspected of interfering with the hormone systems of humans and wildlife (COM(1999)706), (COM (2001)262) and (SEC(2004)1372). Brussels.
   Google Scholar
• Sharpe RM, Skakkeback NE. 2008. Testicular dysgenesis syndrome: mechanistic insights and potential downstream effects. Fertil Steril. 89:e33–e38.
   PubMed Web of Science ®Google Scholar
• Shved N, Berishvili G, Baroiller J-F, Segner H, Reinecke M. 2008. Environmentally relevant concentrations of 17 β-ethinylestradiol (EE2) interfere with the IGF-1 system in developing bony fish. Toxicol Sc I. 106:93–102.
   PubMed Web of Science ®Google Scholar
• Silbergeld EK, Patrick TE. 2005. Environmental exposures, toxicologic mechanisms, and adverse pregnancy outcomes. Am J Obstet Gynecol. 192:S11–S21.
   PubMed Web of Science ®Google Scholar
• Skakkebaek NE, Rajpert-De Meyts E, Main KM. 2001. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod. 16:972–978.
   PubMed Web of Science ®Google Scholar
• Small CM, Manatunga AK, Klein M, Feifelson HS, Dominguez CE, Mcchesney R, Marcus M. 2006. Menstrual cycle characteristics: associations with fertility and spontaneous abortion. Epidemiology. 17:52–60.
   PubMed Web of Science ®Google Scholar
• Sonich-Mullin C, Fielder R, Wiltse J, Baetcke K, Dempsey J, Fenner-Crisp P, Grant D, Hartley M, Knaap A, Kroese D, Mangelsdorf I. 2001. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol. 34:146–152.
   PubMed Web of Science ®Google Scholar
• Soto AM, Vandenberg LN, Maffini MV, Sonnenschein C. 1998. Does breast cancer start in the womb? Basic Clin Pharmacol Toxicol. 102:125–133.
   Web of Science ®Google Scholar
• Suh J, Choi MH, Kwon AR, Kim YJ, Jeong JW, Ahn JM, Cae HW, Kim DH, Kim HS. 2013. Factors that predict a positive response on gonadotropin-releasing hormone stimulation test for diagnosing central precocious puberty in girls. Ann Pediatr Endocrinol Metab. 18:202–207.
   PubMedGoogle Scholar
• Tariverdian N, Theoharides TC, Siedentopf F, Gutierrez G, Jeschke U, Rabinovich GA, Blois SM, Arck PC. 2007. Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach. Semin Immunopathol. 29:193–210.
   PubMed Web of Science ®Google Scholar
• Thayer KA, Foster P. 2007. Workgroup report: National Toxicology Program Workshop on hormonally induced reproductive tumors – relevance of rodent bioassays. Environ Health Perspect. 115:1351–1356. Published online 2007.
   PubMed Web of Science ®Google Scholar
• US Environmental Protection Agency (EPA). 1998. Assessment of thyroid follicular cell tumors. EPA/630/R-97/002. Risk Assessment Forum, Washington, DC 20460.
   Google Scholar
• US Environmental Protection Aency (EPA). 2005. Guidance for thyroid assays in pregnant animals, fetuses and postnatal animals, and adult animals. Office of Pesticide Programs, Health Effects Division, Washington, DC. October 24, 2005. Available from: https://www.epa.gov/sites/production/files/2015-06/documents/thyroid_guidance_assay.pdf.
   Google Scholar
• US Environmental Protection Agency (EPA). 2013. State of the science evaluation: nonmonotonic dose responses as they apply to estrogen, androgen, and thyroid pathways and EPA testing and assessment procedures. Draft. June 2013.
   Google Scholar
• US Environmental Protection Agency (EPA) [Internet]. 2014. Endocrine disruptor screening program test guidelines: three Tier 2 non-mammalian tests. EPA-HQ-OPPT-2014-0766-0018. Available from: https://www.regulations.gov/document?D=EPA-HQ-OPPT-2014-0766-0018
   Google Scholar
• US Environmental Protection Agency (EPA) [Internet]. 2016. What is a human health risk assessment. Available from: https://www.epa.gov/risk
   Google Scholar
• Veeramachaneni DNR, Palmer JS, Amann RP, Pau KYF. 2007. Sequelae in male rabbits following developmental exposure to p,p'-DDT or a mixture of p,p'-DDT and vinclozolin: cryptorchidism, germ cell atypia, and sexual dysfunction. Reprod Toxicol. 23:353–365.
   PubMed Web of Science ®Google Scholar
• Veeramachaneni DNR. 2008. Impact of environmental pollutants on the male: effects on germ cell differentiation. Anim Reprod Sci. 105:144–157.
   PubMed Web of Science ®Google Scholar
• Virtanen HE, Adamsson A. 2012. Cryptorchidism and endocrine disrupting chemicals. Mol Cell Endocrinol. 355:208–220.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Croughan MS, Schembri M, Chan JM, Turek PJ. 2009. Increased risk of testicular germ cell cancer among infertile men. Arch Intern Med. 169:351–356.
   PubMedGoogle Scholar
• World Health Organization (WHO). 2015. Epidemic of obesity and overweight. Fact sheet. Updated June 2016.
   Google Scholar
• Yeager N, Brewer C, Cai KQ, Xu XX, Di CA. 2008. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res. 68:444–449.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Assis R. 2007. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord. 8:331–342.
   PubMed Web of Science ®Google Scholar
• Youngren KK, Nadeau JH, Matin A. 2003. Testicular cancer susceptibility in the 129.MOLF-Chr19 mouse strain: additive effects, gene interactions and epigenetic modifications. Hum Mol Genet. 12:389–398.
   PubMed Web of Science ®Google Scholar
• Zoeller RT, Tan SW, Tyl RW. 2007. General background on the hypothalamic-pituitary-thyroid (HPT) axis. Crit Rev Toxicol. 37:11–53.
   PubMed Web of Science ®Google Scholar
• Zoeller TR. 2010. Environmental chemicals targeting thyroid. Hormones (Athens). 9:28–40.
   PubMedGoogle Scholar